<DOC>
	<DOCNO>NCT02820935</DOCNO>
	<brief_summary>This two-part study conduct single study site US . Both part study may conduct parallel . A total approximately 38 subject participate study , approximately 19 subject Part 1 approximately 19 subject Part 2 . Each subject may participate one part .</brief_summary>
	<brief_title>Study Evaluate Effect Cytochrome P450 ( CYP ) 3A Inhibition Induction Pharmacokinetics CC-220 Healthy Subjects</brief_title>
	<detailed_description>This two part study conduct single study site . Both part study may conduct parallel . A total approximately 38 subject participate study , approximately 19 subject Part 1 approximately 19 subject Part 2 . Each subject may participate one part . Each Part consist 2 study period . Part 1 Part 2 , subject participate Screening phase , one baseline visit per period , one dosing phase per period , follow-up telephone call . In Part 1 , subject receive single dose CC-220 Period 1 , follow appropriate washout , multiple dos itraconazole plus one dose itraconazole CC-220 Period 2 . In Part 2 , subject receive CC-220 Period 1 , follow appropriate washout , multiple dos rifampin plus one dose rifampin CC-220 Period 2 .</detailed_description>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Subjects must satisfy follow criterion enrol study : 1 . Subject ≥ 18 ≤ 65 year age time sign informed consent form ( ICF ) . 2 . Subject must understand voluntarily sign ICF prior studyrelated assessments/procedures conduct . 3 . Subject willing able adhere study visit schedule protocol requirement . 4 . Subject good health determine Physical examination ( PE ) screening . 5 . Subject agree abide requirement restriction outline CC220 Pregnancy Prevention Plan Subjects Clinical Trials . 6 . Female subject childbearing potential must : . Have surgically sterilize ( hysterectomy bilateral oophorectomy ; proper documentation require ) least 6 month screen , postmenopausal ( defined 24 consecutive month without menses screen , folliclestimulating hormone [ FSH ] level &gt; 40 IU/L screening ) . 7 . Male subject must : . Practice true abstinence1 ( must review monthly basis source document ) agree use barrier method birth control ( condom make natural [ animal ] membrane [ latex condom recommend ] ) sexual contact pregnant female female childbearing potential ( FCBP ) 2 participate study , dose interruption , least 28 day last dose investigational Product ( IP ) , even undergone successful vasectomy . 8 . Subject body mass index ( BMI ) ≥ 18 ≤ 33 kg/m2 screening . 1 True abstinence acceptable line prefer usual lifestyle subject ( periodic abstinence [ eg , calendar , ovulation , symptothermal , postovulation method ] withdrawal acceptable method contraception ) . 2 A female childbearing potential ( FCBP ) female : 1 ) achieve menarche point ; 2 ) undergone hysterectomy bilateral oophorectomy ; 3 ) naturally postmenopausal ( amenorrhea follow cancer therapy rule childbearing potential ) least 24 consecutive month ( ie , menses time precede 24 consecutive month ) . 9 . Subject clinical laboratory safety test result within normal limit acceptable Investigator . Platelet count , absolute neutrophil count , absolute lymphocyte count must lower limit normal screening . 10 . Subject afebrile , supine systolic blood pressure ( BP ) ≥ 90 ≤ 140 mmHg , supine diastolic BP ≥ 50 ≤ 90 mmHg , pulse rate ≥ 40 ≤ 110 bpm screening . 11 . Subject normal clinically acceptable 12lead ECG ( Electrocardiogram ) screening . In addition : 1 . If male , subject correct QT value ( base Fridericia 's formula ) ≤ 430 msec screening . 2 . If female , subject correct QT value ( base Fridericia 's formula ) ≤ 450 msec screening . The presence follow exclude subject enrollment : 1 . Subject significant relevant medical condition ( include limited neurological , gastrointestinal , renal , hepatic , cardiovascular , psychological , pulmonary , metabolic , endocrine , hematological , allergic disease , drug allergy , major disorder ) , laboratory abnormality , psychiatric illness would prevent subject participate study . 2 . Subject condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study . 3 . Subject condition confounds ability interpret data study . 4 . Subject female childbearing potential , pregnant , breastfeed . 5 . Subject exposed investigational drug ( new chemical entity ) within 30 day precede first dose administration , five halflives investigational drug , know ( whichever longer ) . 6 . Subject use prescribed systemic topical medication ( include limit analgesic , anesthetic , etc ) within 30 day prior first dose administration . 7 . Subject use nonprescribed systemic topical medication ( include vitamin/mineral supplement , herbal medicine ) within 14 day prior first dose administration . 8 . Subject use CYP3A inducer and/or inhibitor ( include St. John 's wort ) within 30 day prior first dose administration . The Indiana University `` Cytochrome P450 Drug Interaction Table '' utilized determine inhibitor and/or inducer CYP3A . 9 . Subject surgical medical condition possibly affect drug absorption , distribution , metabolism excretion , eg , bariatric procedure . Appendectomy cholecystectomy acceptable . 10 . Subject donate blood plasma within 8 week first dose administration blood bank blood donation center . 11 . Subject history drug abuse ( define current version Diagnostic Statistical Manual [ DSM ] ) within 2 year first dose administration , positive drug screen test reflect consumption illicit drug . 12 . Subject history alcohol abuse ( define current version Diagnostic Statistical Manual ( DSM ) ) within 2 year first dose administration , positive alcohol screen . 13 . Subject know serum hepatitis know carrier hepatitis B surface antigen ( HBsAg ) hepatitis C antibody ( HCV Ab ) , positive result test human immunodeficiency virus ( HIV ) antibodies screen . 14 . Subject smoke &gt; 10 cigarette per day , equivalent tobacco product ( selfreported ) . 15 . Subject part clinical staff personnel family member clinical site staff . 16 . Subject received immunization live live attenuate vaccine within 2 month prior administration first dose IP planning receive immunization live live attenuate vaccine 2 month administration last dose Investigational Product ( IP ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Cytochrome P450</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>CC-220</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>